



## ASX Announcement

### **IMRICOR ANNOUNCES DISTRIBUTION AGREEMENT WITH REGIONAL HEALTH CARE GROUP, EXPANDING REACH TO AUSTRALIA AND NEW ZEALAND**

**31 March 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR)** the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Distribution Agreement with Australian-owned medical distribution company Regional Health Care Group Pty Ltd (RGCH), based in Sydney.

Under the agreement, RHCG will be the exclusive distributor of Imricor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imricor's capital equipment. Importantly, RGCH will also help facilitate the necessary regulatory approvals and support of Imricor's products in Australia and New Zealand. First approvals are expected by year-end 2021.

Regional Health Care Group (RHCG) is an Australian-owned medical distribution company with over 40 years of experience in the Australian medical industry as a provider of medical consumables, contrast media and capital equipment.

The agreement with RHGC enables MRI manufacturers such as Philips to continue providing Imricor's capital equipment as part of an overall iCMR lab package.

Imricor's Chair and CEO, Steve Wedan, said: "We are thrilled to join forces with Regional Healthcare Group to bring Imricor's products and MRI-guided ablations to Australia and New Zealand. This is an important part of our geographical expansion plans, and we can't think of a better partner to work with. Together, we look forward to helping improve the care of Australians and New Zealanders struggling with cardiac arrhythmias."

RHCG General Manager Stephen Doorey added "We are extremely excited to partner with Imricor, their innovative and exciting new solution for Cardiac Ablations is a great addition to our business. RHCG has unrivalled experience in supplying and servicing medical equipment and consumables to the Radiology and Cardiology sector across Australia and New Zealand with over 1,200 devices installed."

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS



## Further Information

### **Investors:**

Steve Wedan  
Executive Chair, President and CEO  
Email: [steve.wedan@imricor.com](mailto:steve.wedan@imricor.com)

### **Investors & Australian Media:**

Brett Ward  
Senior Advisor, Cato & Clive  
Email: [brett@catoandclive.com](mailto:brett@catoandclive.com)  
Mobile: +61 437 994 451

### **Rest of World Media:**

Nick Twohy  
Director of Marketing, Imricor  
Email: [nick.twohy@imricor.com](mailto:nick.twohy@imricor.com)  
Phone: +1 952 818 8407

### **About Imricor**

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

### **Imricor's Products**

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

### **Foreign Ownership Restrictions**

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**



This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.